Placebo Pre-Treat

BEHAVIORAL2 trials

Sponsors

Seres Therapeutics, Inc., Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

Conditions

AgingExercises TherapyFrailtySarcopeniaUlcerative Colitis

Phase 1

A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis

CompletedNCT02618187

Seres Therapeutics, Inc.Ulcerative Colitis

Start: 2016-01-13End: 2018-01-26Updated: 2019-06-20

Unknown Phase

Effect of a Multicomponent Therapeutic Exercise Program in Primary Care on Frailty and Sarcopenia in Older Adults

Not yet recruitingNCT07132632

Fundacio d'Investigacio en Atencio Primaria Jordi Gol i GurinaAging, Exercises Therapy, Frailty +1

Start: 2025-11-02End: 2026-12-31Target: 60Updated: 2025-08-27

Related Papers

A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis.

2020-08-0486 citations